TSH Biopharm Corporation Limited reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 123.71 million compared to TWD 112.16 million a year ago. Revenue was TWD 123.71 million compared to TWD 112.16 million a year ago. Net income was TWD 16.84 million compared to TWD 18.22 million a year ago. Basic earnings per share from continuing operations was TWD 0.44 compared to TWD 0.47 a year ago. Diluted earnings per share from continuing operations was TWD 0.44 compared to TWD 0.47 a year ago.
For the nine months, sales was TWD 367.87 million compared to TWD 342.23 million a year ago. Revenue was TWD 367.87 million compared to TWD 342.23 million a year ago. Net income was TWD 45.79 million compared to TWD 53.92 million a year ago. Basic earnings per share from continuing operations was TWD 1.19 compared to TWD 1.4 a year ago. Diluted earnings per share from continuing operations was TWD 1.19 compared to TWD 1.4 a year ago.